The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Keclor     (6R,7S)-7-[(2-amino-2- phenyl...

Synonyms: Alenfral, Alfacet, Alfatil, Cephaclor, Panacef, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cefaclor


Psychiatry related information on cefaclor

  • A new controlled-delivery, extended-release 500-mg formulation of cefaclor that is administered twice daily may improve patient compliance compared with the older, immediate-release 250-mg formulation that is administered three times daily [6].

High impact information on cefaclor


Chemical compound and disease context of cefaclor


Biological context of cefaclor


Anatomical context of cefaclor


Associations of cefaclor with other chemical compounds


Gene context of cefaclor


Analytical, diagnostic and therapeutic context of cefaclor

  • LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and amoxicillin-clavulanic acid [33].
  • The cure rates at 1 and 4 weeks after treatment were 96 and 78%, respectively, in the AM-CL group and 92 and 75%, respectively, in the cefaclor group (P greater than 0.10) [34].
  • An open, multicentre study involving 259 children between 6 months and 13 years of age was performed to assess the efficacy and safety of azithromycin and to compare it with cefaclor as treatment of acute otitis media [35].
  • Following a 3-week recovery, the rate of gastric emptying of saline, peptone (4.5%) or cefaclor was determined after instillation into the gastric cannula, while intestinal transit was measured by using the propagation of arabic gum + charcoal mixture given intraduodenally [20].
  • The efficacy of cefaclor and rifampin in eradicating Haemophilus influenzae type b (HITB) from the nasopharynx of day care center and household contacts of children with HITB meningitis was evaluated [36].


  1. Cefaclor serum sickness. Grammer, L.C. JAMA (1996) [Pubmed]
  2. High incidence of anaphylactic reactions to cefaclor. Hama, R., Mori, K. Lancet (1988) [Pubmed]
  3. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Schleupner, C.J., Anthony, W.C., Tan, J., File, T.M., Lifland, P., Craig, W., Vogelman, B. Arch. Intern. Med. (1988) [Pubmed]
  4. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population. McCarty, J., Ruoff, G.E., Jacobson, K.D. Am. J. Med. (1992) [Pubmed]
  5. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis. Hyslop, D.L., Bischoff, W. Am. J. Med. (1992) [Pubmed]
  6. Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms. Cole, P. Clinical therapeutics. (1997) [Pubmed]
  7. Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase. Spencer, J., Clarke, A.R., Walsh, T.R. J. Biol. Chem. (2001) [Pubmed]
  8. Acute bronchitis: results of U.S. and European trials of antibiotic therapy. Dere, W.H. Am. J. Med. (1992) [Pubmed]
  9. Emergence and persistence of beta-lactamase-producing bacteria in the upper respiratory tract in children treated with beta-lactam antibiotics. Eliasson, I., Holst, E., Mölstad, S., Kamme, C. Am. J. Med. (1990) [Pubmed]
  10. Single-dose cefaclor therapy of urinary tract infection. Evaluation of antibody-coated bacteria test and C-reactive protein assay as predictors of cure. Greenberg, R.N., Sanders, C.V., Lewis, A.C., Marier, R.L. Am. J. Med. (1981) [Pubmed]
  11. Measurement of cefaclor and amoxicillin-clavulanic acid levels in middle-ear fluid in patients with acute otitis media. Scaglione, F., Caronzolo, D., Pintucci, J.P., Fraschini, F. Antimicrob. Agents Chemother. (2003) [Pubmed]
  12. BMY 28100, a new oral cephalosporin. Leitner, F., Pursiano, T.A., Buck, R.E., Tsai, Y.H., Chisholm, D.R., Misiek, M., Desiderio, J.V., Kessler, R.E. Antimicrob. Agents Chemother. (1987) [Pubmed]
  13. Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis. Christenson, J.C., Swenson, E., Gooch, W.M., Herrod, J.N. Antimicrob. Agents Chemother. (1991) [Pubmed]
  14. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential. Brogden, R.N., Campoli-Richards, D.M. Drugs (1989) [Pubmed]
  15. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Dagan, R., Leibovitz, E., Fliss, D.M., Leiberman, A., Jacobs, M.R., Craig, W., Yagupsky, P. Antimicrob. Agents Chemother. (2000) [Pubmed]
  16. In vitro activity of Ro 15-8074, a new oral cephalosporin, against Neisseria gonorrhoeae. Ng, W.S., Chau, P.Y., Leung, Y.K., Wong, P.C. Antimicrob. Agents Chemother. (1985) [Pubmed]
  17. Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis. Spyker, D.A., Gober, L.L., Scheld, W.M., Sande, M.A., Bolton, W.K. Antimicrob. Agents Chemother. (1982) [Pubmed]
  18. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Nagai, K., Davies, T.A., Jacobs, M.R., Appelbaum, P.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  19. In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral beta-lactam antibiotics is associated with alterations of PBP2x. Sifaoui, F., Kitzis, M.D., Gutmann, L. Antimicrob. Agents Chemother. (1996) [Pubmed]
  20. Cefaclor, a cephalosporin antibiotic, delays gastric emptying rate by a CCK-A receptor-mediated mechanism in the rat. Bozkurt, A., Deniz, M., Yegen, B.C. Br. J. Pharmacol. (2000) [Pubmed]
  21. Penetration of cefaclor into bronchial mucosa. Marlin, G.E., Nicholls, A.J., Funnell, G.R., Bradbury, R. Thorax (1984) [Pubmed]
  22. Concentration relationships of cefaclor in serum, interstitial fluid, bile, and urine of dogs. Waterman, N.G., Scharfenberger, L.F. Antimicrob. Agents Chemother. (1978) [Pubmed]
  23. Susceptibility of Haemophilus influenzae type b to cefaclor and influence of inoculum size. Levin, R.M., Azimi, P.H., Dunphy, M.G. Antimicrob. Agents Chemother. (1982) [Pubmed]
  24. Effects of cefaclor, cefetamet and Ro 40-6890 on inflammatory responses of human granulocytes. Scheffer, J., Knöller, J., Cullmann, W., König, W. J. Antimicrob. Chemother. (1992) [Pubmed]
  25. Single-dose cefuroxime axetil versus multiple-dose cefaclor in the treatment of acute urinary tract infections. Iravani, A., Richard, G.A. Antimicrob. Agents Chemother. (1989) [Pubmed]
  26. Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections. Markham, A., Brogden, R.N. Drugs (1995) [Pubmed]
  27. Comparison of cefprozil and cefaclor for treatment of acute urinary tract infections in women. Iravani, A. Antimicrob. Agents Chemother. (1991) [Pubmed]
  28. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Li, M., Anderson, G.D., Phillips, B.R., Kong, W., Shen, D.D., Wang, J. Drug Metab. Dispos. (2006) [Pubmed]
  29. Competition of IL-1 and IL-1ra determines lymphocyte response to delayed stimulation with PHA. Dabrowski, M.P., Stankiewicz, W., Płusa, T., Chciałowski, A., Szmigielski, S. Mediators of inflammation. (2001) [Pubmed]
  30. Clinical and pro-host effects of cefaclor in prophylaxis of recurrent otitis media in HIV-infected children. Zuccotti, G., Dauria, E., Torcoletti, M., Lodi, F., Bernardo, L., Riva, E. J. Int. Med. Res. (2001) [Pubmed]
  31. Different patterns of cytokines, ECP and immunoglobulin profiles at two adverse drug reactions in a patient. Aihara, Y., Ito, S., Aihara, M., Kobayashi, Y., Yokota, S. Pediatrics international : official journal of the Japan Pediatric Society. (2005) [Pubmed]
  32. In-vitro activity and beta-lactamase stability of LY163892. Cao, C., Chin, N.X., Neu, H.C. J. Antimicrob. Chemother. (1988) [Pubmed]
  33. In vitro susceptibilities of common pediatric pathogens to LY163892. Shelton, S., Nelson, J.D. Antimicrob. Agents Chemother. (1988) [Pubmed]
  34. Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Iravani, A., Richard, G.A. Antimicrob. Agents Chemother. (1986) [Pubmed]
  35. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. Rodriguez, A.F. J. Antimicrob. Chemother. (1996) [Pubmed]
  36. Nasopharyngeal carriage of Haemophilus influenzae type b: attempted eradication by cefaclor or rifampin. Yogev, R., Melick, C., Kabat, K. Pediatrics (1981) [Pubmed]
WikiGenes - Universities